Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $1.0 million.

  • Avalo Therapeutics' Change in Accured Expenses rose 21915.89% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 17527.69%. This contributed to the annual value of -$1.1 million for FY2024, which is 8772.1% up from last year.
  • Per Avalo Therapeutics' latest filing, its Change in Accured Expenses stood at $1.0 million for Q3 2025, which was up 21915.89% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Change in Accured Expenses peaked at $3.2 million during Q2 2021, and registered a low of -$4.9 million during Q1 2023.
  • Its 5-year average for Change in Accured Expenses is -$485736.8, with a median of -$686000.0 in 2023.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 131408.45% in 2021, then plummeted by 72620.87% in 2023.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Change in Accured Expenses stood at $646000.0 in 2021, then crashed by 175.54% to -$488000.0 in 2022, then plummeted by 96.72% to -$960000.0 in 2023, then soared by 204.06% to $999000.0 in 2024, then rose by 2.1% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $2.0 million for Q2 2025, and -$1.7 million during Q1 2025.